Published in Semin Liver Dis on October 27, 2008
Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian | NCT04081571
Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology (2010) 3.73
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ (2011) 3.69
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology (2011) 3.00
The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol (2010) 2.50
Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology (2010) 2.50
Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2013) 2.50
Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.25
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol (2011) 2.15
Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci (2014) 2.03
Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology (2013) 1.78
From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol (2013) 1.75
The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab (2012) 1.66
Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol (2013) 1.56
What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol (2013) 1.49
Nonalcoholic fatty liver disease. J Lipid Res (2008) 1.47
A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol (2010) 1.38
Think small: zebrafish as a model system of human pathology. J Biomed Biotechnol (2012) 1.30
Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol (2014) 1.29
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol (2012) 1.27
Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol (2014) 1.25
Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids (2011) 1.23
Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr (2014) 1.20
Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol (2010) 1.18
Major facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolism. PLoS One (2012) 1.17
Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.17
Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol (2012) 1.14
CTRP3 attenuates diet-induced hepatic steatosis by regulating triglyceride metabolism. Am J Physiol Gastrointest Liver Physiol (2013) 1.11
Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev (2011) 1.07
Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage? World J Gastroenterol (2013) 1.06
Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol (2014) 1.06
Prevalence of Nonalcoholic Steatohepatitis in Iran: A Population based Study. Middle East J Dig Dis (2010) 1.04
Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol (2015) 1.00
Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol (2013) 1.00
Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers. Cell Metab (2014) 0.99
Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. Cell Cycle (2014) 0.98
Lessons from mouse models of high-fat diet-induced NAFLD. Int J Mol Sci (2013) 0.97
Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One (2012) 0.97
Vitamin D: a new player in non-alcoholic fatty liver disease? World J Gastroenterol (2015) 0.96
Mitochondria and redox signaling in steatohepatitis. Antioxid Redox Signal (2011) 0.96
Alcohol-related and viral hepatitis C-related cirrhosis mortality among Hispanic subgroups in the United States, 2000-2004. Alcohol Clin Exp Res (2010) 0.95
Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol Hepatol (N Y) (2013) 0.94
Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon (2013) 0.93
Severe diabetes and leptin resistance cause differential hepatic and renal transporter expression in mice. Comp Hepatol (2012) 0.93
Inositol 1,4,5-trisphosphate receptor type II (InsP3R-II) is reduced in obese mice, but metabolic homeostasis is preserved in mice lacking InsP3R-II. Am J Physiol Endocrinol Metab (2014) 0.92
The genetic architecture of NAFLD among inbred strains of mice. Elife (2015) 0.92
Oxidative stress and altered lipid homeostasis in the programming of offspring fatty liver by maternal obesity. Am J Physiol Regul Integr Comp Physiol (2014) 0.92
Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients (2014) 0.92
The effects of low carbohydrate diets on liver function tests in nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. J Res Med Sci (2016) 0.91
Defining hepatic dysfunction parameters in two models of fatty liver disease in zebrafish larvae. Zebrafish (2013) 0.91
Inflammatory mediators of hepatic steatosis. Mediators Inflamm (2010) 0.91
Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr (2014) 0.90
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr (2012) 0.89
Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One (2014) 0.89
Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol (2015) 0.89
Methyl-donor supplementation in obese mice prevents the progression of NAFLD, activates AMPK and decreases acyl-carnitine levels. Mol Metab (2014) 0.89
Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. Hepatology (2016) 0.89
Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease. Iran Red Crescent Med J (2014) 0.88
Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol (2013) 0.87
Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease. PLoS One (2015) 0.87
Coordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates. PLoS One (2011) 0.87
NAFLD prevalence differs among hispanic subgroups: the Multi-Ethnic Study of Atherosclerosis. World J Gastroenterol (2014) 0.86
Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging (2014) 0.86
Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol (2014) 0.86
Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly. Curr Gerontol Geriatr Res (2011) 0.86
Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol (2013) 0.86
Revising the upper limit of normal for levels of serum alanine aminotransferase in a Middle Eastern population with normal liver histology. Dig Dis Sci (2013) 0.86
Effects of increased dietary cholesterol with carbohydrate restriction on hepatic lipid metabolism in Guinea pigs. Comp Med (2012) 0.85
Digital analysis of hepatic sections in mice accurately quantitates triglycerides and selected properties of lipid droplets. Exp Biol Med (Maywood) (2010) 0.85
Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. Clin Mol Hepatol (2013) 0.85
Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol (2012) 0.84
Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatol Res (2011) 0.84
BL153 partially prevents high-fat diet induced liver damage probably via inhibition of lipid accumulation, inflammation, and oxidative stress. Oxid Med Cell Longev (2014) 0.83
Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. Hepat Med (2010) 0.83
Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice. Hepatology (2014) 0.83
An exploration of prevalence and associated factors of nonalcoholic Fatty liver disease in the taiwanese police service. Iran J Public Health (2011) 0.83
Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig Dis Sci (2011) 0.83
Effects of acute exercise and chronic exercise on the liver leptin-AMPK-ACC signaling pathway in rats with type 2 diabetes. J Diabetes Res (2013) 0.83
Downregulation of sulfotransferase expression and activity in diseased human livers. Drug Metab Dispos (2013) 0.82
Plasma levels of homocysteine and cysteine increased in pediatric NAFLD and strongly correlated with severity of liver damage. Int J Mol Sci (2014) 0.82
Multi-omic profiles of human non-alcoholic fatty liver disease tissue highlight heterogenic phenotypes. Sci Data (2015) 0.82
NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol (2016) 0.81
Hemochromatosis gene and nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2011) 0.81
Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.81
Tumor necrosis factor α-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice. PLoS One (2011) 0.81
Elevated alanine aminotransferase activity is not associated with dyslipidemias, but related to insulin resistance and higher disease grades in non-diabetic non-alcoholic fatty liver disease. Asian Pac J Trop Biomed (2012) 0.81
Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. Gut Liver (2016) 0.81
Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr(-/-) mouse model. Sci Rep (2015) 0.81
Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome (2014) 0.80
Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. World J Hepatol (2015) 0.80
Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol (2014) 0.80
The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. J Hepatol (2014) 0.80
The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid Res (2014) 0.80
Fructus Xanthii attenuates hepatic steatosis in rats fed on high-fat diet. PLoS One (2013) 0.80
Clinical correlation of nonalcoholic fatty liver disease in a Chinese taxi drivers population in Taiwan: Experience at a teaching hospital. BMC Res Notes (2011) 0.80
Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example. PLoS One (2013) 0.80
Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocell Carcinoma (2014) 0.80
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med (2011) 7.81
Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med (2008) 5.27
Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA (2012) 5.15
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med (2013) 4.25
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med (2015) 3.79
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ (2011) 3.69
Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity (Silver Spring) (2011) 3.62
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2013) 2.50
Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect (2006) 2.44
Impact of bariatric surgery on health care costs of obese persons: a 6-year follow-up of surgical and comparison cohorts using health plan data. JAMA Surg (2013) 2.39
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol (2011) 2.15
Barriers to and facilitators of postpartum follow-up care in women with recent gestational diabetes mellitus: a qualitative study. J Womens Health (Larchmt) (2011) 2.05
The effectiveness of a community/academic health center partnership in decreasing the level of blood pressure in an urban African-American population. Ethn Dis (2003) 1.94
Independent but coordinated trials: insights from the practice-based Opportunities for Weight Reduction Trials Collaborative Research Group. Clin Trials (2010) 1.93
Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care (2004) 1.90
The impact of obesity on breast surgery complications. Plast Reconstr Surg (2011) 1.88
Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med (2008) 1.82
Surgical site infections and cost in obese patients undergoing colorectal surgery. Arch Surg (2011) 1.78
Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol (2013) 1.77
Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study. J Diabetes Complications (2008) 1.77
Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) (2010) 1.64
Obesity and mammography: a systematic review and meta-analysis. J Gen Intern Med (2009) 1.57
Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology (2012) 1.57
A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol (2007) 1.55
Physician respect for patients with obesity. J Gen Intern Med (2009) 1.55
Impact of bariatric surgery on health care utilization and costs among patients with diabetes. Med Care (2012) 1.49
Effect of gastric bypass surgery on kidney stone disease. J Urol (2009) 1.48
Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci (2004) 1.46
Laboratory testing for and diagnosis of nutritional deficiencies in pregnancy before and after bariatric surgery. J Womens Health (Larchmt) (2013) 1.42
Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care (2010) 1.40
Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. J Nerv Ment Dis (2003) 1.37
The association of obesity and cervical cancer screening: a systematic review and meta-analysis. Obesity (Silver Spring) (2008) 1.36
Racial and socioeconomic differences in the weight-loss experiences of obese women. Am J Public Health (2005) 1.30
Weight loss strategies associated with BMI in overweight adults with type 2 diabetes at entry into the Look AHEAD (Action for Health in Diabetes) trial. Diabetes Care (2008) 1.28
Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology (2003) 1.25
Does genetic ancestry explain higher values of glycated hemoglobin in African Americans? Diabetes (2011) 1.23
The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med (2013) 1.22
Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery. Arch Surg (2010) 1.19
Prompt reduction in use of medications for comorbid conditions after bariatric surgery. Obes Surg (2009) 1.14
Development and validation of a model for predicting inpatient hospitalization. Med Care (2012) 1.09
Clinical outcomes after bariatric surgery: a five-year matched cohort analysis in seven US states. Obes Surg (2012) 1.07
Early response to preventive strategies in the Diabetes Prevention Program. J Gen Intern Med (2013) 1.06
Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg Obes Relat Dis (2006) 1.05
Utilization of primary and obstetric care after medically complicated pregnancies: an analysis of medical claims data. J Gen Intern Med (2014) 1.05
The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care (2014) 1.03
Doctor shopping by overweight and obese patients is associated with increased healthcare utilization. Obesity (Silver Spring) (2013) 1.01
Insights from the POWER practice-based weight loss trial: a focus group study on the PCP's role in weight management. J Gen Intern Med (2013) 0.97
Disparity in physician perception of patients' adherence to medications by obesity status. Obesity (Silver Spring) (2010) 0.97
The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol (2008) 0.96
Changes in weight and health behaviors after pregnancies complicated by gestational diabetes mellitus: the CARDIA study. Obesity (Silver Spring) (2013) 0.96
Impact of bariatric surgery on hypertensive disorders in pregnancy: retrospective analysis of insurance claims data. BMJ (2010) 0.94
Outcomes of a national faculty development program in teaching skills: prospective follow-up of 110 medicine faculty development teams. J Gen Intern Med (2004) 0.94
Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity (Silver Spring) (2013) 0.93
Greater weight loss with increasing age in the weight loss maintenance trial. Obesity (Silver Spring) (2013) 0.92
Primary care providers' communication with patients during weight counseling: a focus group study. Patient Educ Couns (2012) 0.91
Effectiveness of an Activity Tracker- and Internet-Based Adaptive Walking Program for Adults: A Randomized Controlled Trial. J Med Internet Res (2016) 0.90
Screening and diagnosis of micronutrient deficiencies before and after bariatric surgery. Obes Surg (2013) 0.89
Prevalence of and risk factors for hypoglycemic symptoms after gastric bypass and sleeve gastrectomy. Obesity (Silver Spring) (2015) 0.89
A randomized trial of exercise for blood pressure reduction in type 2 diabetes: effect on flow-mediated dilation and circulating biomarkers of endothelial function. Atherosclerosis (2012) 0.88
Intensive weight loss intervention in older individuals: results from the Action for Health in Diabetes Type 2 diabetes mellitus trial. J Am Geriatr Soc (2013) 0.88
Body mass index and colon cancer screening: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 0.88
Low glycated hemoglobin and liver disease in the U.S. population. Diabetes Care (2011) 0.87
Hepatic fat and adenosine triphosphate measurement in overweight and obese adults using 1H and 31P magnetic resonance spectroscopy. Liver Int (2008) 0.87
Lifetime weight patterns in male physicians: the effects of cohort and selective survival. Obesity (Silver Spring) (2006) 0.86
Hepatic 31P magnetic resonance spectroscopy: a hepatologist's user guide. Liver Int (2005) 0.86
Effect of exercise on blood pressure in type 2 diabetes: a randomized controlled trial. J Gen Intern Med (2012) 0.86
Risk of complications after bariatric surgery among individuals with and without type 2 diabetes mellitus. Surg Obes Relat Dis (2011) 0.86
Reduced incidence of gestational diabetes with bariatric surgery. J Am Coll Surg (2010) 0.85
Longitudinal accuracy of web-based self-reported weights: results from the Hopkins POWER Trial. J Med Internet Res (2014) 0.85
Negative trials in nonalcoholic steatohepatitis: why they happen and what they teach us. Hepatology (2004) 0.83
Trends in and patterns of obesity reduction medication use in an insured cohort. Obesity (Silver Spring) (2009) 0.82
Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study. Eur J Prev Cardiol (2012) 0.81
Hemochromatosis gene and nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2011) 0.81
Faculty development needs. J Gen Intern Med (2004) 0.81
Efficacy of Commercial Weight-Loss Programs. Ann Intern Med (2015) 0.81
Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population? J Gastroenterol Hepatol (2011) 0.80
Effect of zinc supplementation on insulin secretion: interaction between zinc and SLC30A8 genotype in Old Order Amish. Diabetologia (2014) 0.79
Morbidity trajectories as predictors of utilization: multi-year disease patterns in Taiwan's national health insurance program. Med Care (2011) 0.79
Oral contraceptive pill use is associated with reduced odds of nonalcoholic fatty liver disease in menstruating women: results from NHANES III. J Gastroenterol (2012) 0.79
Does bariatric surgery affect urinary incontinence? Urology (2013) 0.78
The association of arterial shear and flow-mediated dilation in diabetes. Vasc Med (2011) 0.78
From efficacy to effectiveness: lessons learned from the Practice-Based Opportunities for Weight Reduction (POWER) trial. J Comp Eff Res (2012) 0.78
Prepregnancy body mass index and cardiovascular disease mortality: the Child Health and Development Studies. Obesity (Silver Spring) (2013) 0.77
Variation in Provider Identification of Obesity by Individual- and Neighborhood-Level Characteristics among an Insured Population. J Obes (2010) 0.77
A national collaboration to disseminate skills for outpatient teaching in internal medicine: program description and preliminary evaluation. Acad Med (2006) 0.77
Willingness to pay for continued delivery of a lifestyle-based weight loss program: The Hopkins POWER trial. Obesity (Silver Spring) (2014) 0.75
Prior doctor shopping resulting from differential treatment correlates with differences in current patient-provider relationships. Obesity (Silver Spring) (2014) 0.75
For the patient. Community health workers help to reduce high blood pressure. Ethn Dis (2003) 0.75
Measurement of weight in clinical trials: is one day enough? J Obes (2010) 0.75
Implementing the Comprehensive Unit-Based Safety Program (CUSP) to Improve Patient Safety in an Academic Primary Care Practice. Jt Comm J Qual Patient Saf (2017) 0.75
A screening tool to assess and manage behavioral risk in the postoperative bariatric surgery patient: The WATCH. J Clin Psychol Med Settings (2013) 0.75
Change in claims-based diabetes medications is a diabetes improvement indicator. Am J Manag Care (2013) 0.75